Molecular Partners Selects MP0730 As Lead CD70-Targeting Radio-DARPin For Targeted Alpha Therapy In Kidney Cancer, Third Radiotherapeutics Program; First-In-Human Expected 2027

Loading news article.

Molecular Partners Selects MP0730 As Lead CD70-Targeting Radio-DARPin For Targeted Alpha Therapy In Kidney Cancer, Third Radiotherapeutics Program; First-In-Human Expected 2027 | WAPE

Molecular Partners Selects MP0730 As Lead CD70-Targeting Radio-DARPin For Targeted Alpha Therapy In Kidney Cancer, Third Radiotherapeutics Program; First-In-Human Expected 2027

Article summary

Related companies

Analyzed by WAPE AI.

Comments —